Search

Your search keyword '"Cook, Gordon"' showing total 2,229 results
Start Over Author "Cook, Gordon"
2,229 results on '"Cook, Gordon"'

4. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Author

Cook, Gordon, Ashcroft, A John, Senior, Ethan, Olivier, Catherine, Hockaday, Anna, Richards, Jeanine, Cavenagh, Jamie D, Snowden, John A, Drayson, Mark T, de Tute, Ruth, Roberts, Lesley, Owen, Roger G, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Cook, Mark, Cairns, David A, and Parrish, Christopher

Published
2024
Full Text
View/download PDF

5. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Author

Barnes, Eleanor, Goodyear, Carl S., Willicombe, Michelle, Gaskell, Charlotte, Siebert, Stefan, I de Silva, Thushan, Murray, Sam M., Rea, Daniel, Snowden, John A., Carroll, Miles, Pirrie, Sarah, Bowden, Sarah J., Dunachie, Susanna J., Richter, Alex, Lim, Zixiang, Satsangi, Jack, Cook, Gordon, Pope, Ann, Hughes, Ana, Harrison, Molly, Lim, Sean H., Miller, Paul, Klenerman, Paul, Basu, Neil, Gilmour, Ashley, Irwin, Sophie, Meacham, Georgina, Marjot, Thomas, Dimitriadis, Stavros, Kelleher, Peter, Prendecki, Maria, Clarke, Candice, Mortimer, Paige, McIntyre, Stacey, Selby, Rachael, Meardon, Naomi, Nguyen, Dung, Tipton, Tom, Longet, Stephanie, Laidlaw, Stephen, Orchard, Kim, Ireland, Georgina, Thomas, David, Kearns, Pamela, Kirkham, Amanda, and McInnes, Iain B.

Published
2023
Full Text
View/download PDF

6. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Beesley, Richard, Churchill, Vicky, Insch, Elspeth, Loughton, Holly, MacDonald, Eilean, Lax, Siân, Lowe, Faye, Magwaro, Sophia, Gradwell, Mark, Kinsella, Francesca, Rolfe, Hayley, McIntyre, Stacey, Mortimer, Paige, Al-Taei, Saly, Tadros, Susan, Workman, Sarita, Arnott, Maxine, Brock, James, Melville, Andrew, Najm, Aurelie, Rutherford, Matthew, Sunzini, Flavia, Herman, Lou S, Hobbs, Agnieszka, Ragno, Martina, Wu, Mary Y, Selby, Rachael, Clay, Jennifer, Hutchison, Clare, Lown, Robert, Lwin, May N, Meardon, Naomi, Kelleher, Peter, Lightstone, Liz, Walters, Thomas, Denyer, Jayne, Ibrahim, Rahima, Gleeson, Sarah, Martin, Paul, McAdoo, Stephen, Baker, Helena, Horswill, Sarah, Parungao, Nina, Saich, Stephen, Cullinane, James, Irwin, Sophie, Klenerman, Paul, Marjot, Thomas, Chakraverty, Ronjon, Holroyd, Christopher, Kavi, Janki, Trown, Doreen, Babbage, Gavin, Chackathayil, Julia, Faria, Patricia, Ingham, Karen, Miah, Murad, Miranda, Mauro, O'Reilly, Nicola, Smith, Callie, Driver, Kimberley, Gauntlett, Kaylee, Farthing, Andrew, Rundell, Suzann, Smith, Emily, Tong, Andrew, Woolcock, Kieran, Hanke, Daniel, Laidlaw, Stephen, Malik, Zainab, Nguyen, Dung, Provine, Nicholas, Tipton, Tom, Walker, Victoria, Goodyear, Carl S, Patel, Amit, Barnes, Eleanor, Willicombe, Michelle, Siebert, Stefan, de Silva, Thushan I, Snowden, John A, Lim, Sean H, Bowden, Sarah J, Billingham, Lucinda, Richter, Alex, Carroll, Miles, Carr, Edward J, Beale, Rupert, Rea, Daniel, Parry, Helen, Pirrie, Sarah, Lim, Zixiang, Satsangi, Jack, Dunachie, Susanna J, Cook, Gordon, Miller, Paul, Basu, Neil, Gilmour, Ashley, Hodgkins, Anne-Marie, Evans, Lili, Hughes, Ana, Longet, Stephanie, Meacham, Georgina, Yong, Kwee L, A'Hearne, Matthew J, Koh, Mickey B C, Burns, Siobhan O, Orchard, Kim, Paterson, Caron, McIlroy, Graham, Murray, Sam M, Thomson, Tina, Dimitriadis, Stavros, Goulston, Lyndsey, Miller, Samantha, Keillor, Victoria, Prendecki, Maria, Thomas, David, Kirkham, Amanda, McInnes, Iain B, and Kearns, Pamela

Published
2024
Full Text
View/download PDF

7. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Author

Terpos, Evangelos, Musto, Pellegrino, Engelhardt, Monika, Delforge, Michel, Cook, Gordon, Gay, Francesca, van de Donk, Niels W. C. J., Ntanasis-Stathopoulos, Ioannis, Vangsted, Annette Juul, Driessen, Christoph, Schjesvold, Fredrik, Cerchione, Claudio, Zweegman, Sonja, Hajek, Roman, Moreau, Philippe, Einsele, Hermann, San-Miguel, Jesus, Boccadoro, Mario, Dimopoulos, Meletios A., Sonneveld, Pieter, and Ludwig, Heinz

Published
2023
Full Text
View/download PDF

8. Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study

Author

Keaveney, Sam, Dragan, Alina, Rata, Mihaela, Blackledge, Matthew, Scurr, Erica, Winfield, Jessica M., Shur, Joshua, Koh, Dow-Mu, Porta, Nuria, Candito, Antonio, King, Alexander, Rennie, Winston, Gaba, Suchi, Suresh, Priya, Malcolm, Paul, Davis, Amy, Nilak, Anjumara, Shah, Aarti, Gandhi, Sanjay, Albrizio, Mauro, Drury, Arnold, Pratt, Guy, Cook, Gordon, Roberts, Sadie, Jenner, Matthew, Brown, Sarah, Kaiser, Martin, and Messiou, Christina

Published
2023
Full Text
View/download PDF

11. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

Author

Davies, Faith, Rifkin, Robert, Costello, Caitlin, Morgan, Gareth, Usmani, Saad, Abonour, Rafat, Palumbo, Antonio, Romanus, Dorothy, Hajek, Roman, Terpos, Evangelos, Cherepanov, Dasha, Stull, Dawn, Huang, Hui, Leleu, Xavier, Berdeja, Jesus, Lee, Hans, Weisel, Katja, Thompson, Michael, Boccadoro, Mario, Zonder, Jeffrey, Cook, Gordon, Puig, Noemi, Vela-Ojeda, Jorge, Farrelly, Eileen, Raju, Aditya, Blazer, Marlo, and Chari, Ajai

Subjects
Bortezomib, Carfilzomib, Daratumumab, Ixazomib, Lenalidomide, Pomalidomide, Proteasome inhibitor triplet therapy, Real-world, Relapsed refractory multiple myeloma, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Boron Compounds, Bortezomib, Female, Glycine, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides, Retrospective Studies, Treatment Outcome
Abstract

Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conducted an RW comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D) combined with either lenalidomide or pomalidomide plus dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients initiating triplet regimens in line of therapy (LOT) ≥ 2 on/after 1/1/2014 was followed between 1/2007 and 3/2018 in Optums deidentified US electronic health records database. Time to next treatment (TTNT) was estimated using Kaplan-Meier methods; regimens were compared using covariate-adjusted Cox proportional hazard models. Seven hundred forty-one patients (820 patient LOTs) with an Rd backbone (VRd, n = 349; KRd, n = 218; DRd, n = 99; IRd, n = 154) and 348 patients (392 patient LOTs) with a Pd backbone (VPd, n = 52; KPd, n = 146; DPd, n = 149; IPd, n = 45) in LOTs ≥2 were identified. More patients ≥75 years received IRd (39.6%), IPd (37.8%), and VRd (36.7%) than other triplets. More patients receiving VRd/VPd were in LOT2 vs other triplets. Unadjusted median TTNT in LOT ≥ 2: VRd, 13.9; KRd, 8.7; IRd, 11.4; DRd, not estimable (NE); and VPd, 12.0; KPd, 6.7; IPd, 9.5 months; DPd, NE. In covariate-adjusted analysis, only KRd vs DRd was associated with a significantly higher risk of next LOT initiation/death (HR 1.72; P = 0.0142); no Pd triplet was significantly different vs DPd in LOT ≥ 2. Our data highlight important efficacy/effectiveness gaps between results observed in phase 3 clinical trials and those realized in the RW.

Published
2021

12. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Author

Terpos, Evangelos, Mikhael, Joseph, Hajek, Roman, Chari, Ajai, Zweegman, Sonja, Lee, Hans C, Mateos, María-Victoria, Larocca, Alessandra, Ramasamy, Karthik, Kaiser, Martin, Cook, Gordon, Weisel, Katja C, Costello, Caitlin L, Elliott, Jennifer, Palumbo, Antonio, and Usmani, Saad Z

Subjects
Comparative Effectiveness Research, Health Services, Rare Diseases, Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Hematology, Orphan Drug, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Agents, Clinical Trials, Phase III as Topic, Disease Management, Humans, Multiple Myeloma, Quality of Life, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis
Abstract

Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the 'efficacy' of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual's composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting.

Published
2021

13. Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma

Author

Brownlie, Rebecca J., Kennedy, Ruth, Wilson, Erica B., Milanovic, Maja, Taylor, Claire F., Wang, Dapeng, Davies, John R., Owston, Heather, Adams, Emma J., Stephenson, Sophie, Caeser, Rebecca, Gewurz, Benjamin E., Giannoudis, Peter V., Scuoppo, Claudio, McGonagle, Dennis, Hodson, Daniel J., Tooze, Reuben M., Doody, Gina M., Cook, Gordon, Westhead, David R., and Klein, Ulf

Published
2023
Full Text
View/download PDF

14. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

Author

Jones, John R., Cairns, David A., Menzies, Tom, Pawlyn, Charlotte, Davies, Faith E., Sigsworth, Rachel, Brioli, Annamaria, Jenner, Matthew W., Kaiser, Martin F., Olivier, Catherine, Reed, Molly, Drayson, Mark T., Owen, Roger G., Boyd, Kevin D., Cook, Gordon, Morgan, Gareth J., and Jackson, Graham H.

Published
2023
Full Text
View/download PDF

15. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.

Author

Kaufman, Jonathan, Dimopoulos, Meletios, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather, Magen, Hila, Iida, Shinsuke, Kim, Jin, Miles Prince, H, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar, Chari, Ajai, ORourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad, and San-Miguel, Jesus

Subjects
Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chromosome Deletion, Chromosomes, Human, Cytogenetic Analysis, Dexamethasone, Disease-Free Survival, Humans, Lenalidomide, Multiple Myeloma, Recurrence, Survival Rate, Translocation, Genetic
Abstract

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10-5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P

Published
2020

19. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Author

Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, van Rhee, Frits, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hájek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesus G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, and Chari, Ajai

Published
2023
Full Text
View/download PDF

20. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Author

Costello, Caitlin, Davies, Faith E, Cook, Gordon, Vela-Ojeda, Jorge, Omel, Jim, Rifkin, Robert M, Berdeja, Jesus, Puig, Noemi, Usmani, Saad Z, Weisel, Katja, Zonder, Jeffrey A, Terpos, Evangelos, Spencer, Andrew, Leleu, Xavier, Boccadoro, Mario, Thompson, Michael A, Romanus, Dorothy, Stull, Dawn M, and Hungria, Vania

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Comparative Effectiveness Research, Hematology, Orphan Drug, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Follow-Up Studies, Humans, International Agencies, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Prospective Studies, Quality of Life, Treatment Outcome, Young Adult, multiple myeloma, observational study, treatment, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187.

Published
2019

21. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Author

Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

22. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Author

Dhakal, Binod, Shah, Nina, Kansagra, Ankit, Kumar, Ambuj, Lonial, Sagar, Garfall, Alfred, Cowan, Andrew, Poudyal, Bishesh Sharma, Costello, Caitlin, Gay, Francesca, Cook, Gordon, Quach, Hang, Einsele, Herman, Schriber, Jeff, Hou, Jian, Costa, Luciano, Aljurf, Mahmoud, Chaudhry, Maria, Beksac, Meral, Prince, Miles, Mohty, Mohamad, Janakiram, Murali, Callander, Natalie, Biran, Noa, Malhotra, Pankaj, Otero, Paula Rodriguez, Moreau, Philippe, Abonour, Rafat, Iftikhar, Raheel, Silberman, Rebecca, Mailankody, Sham, Gregory, Tara, Lin, Yi, Carpenter, Paul, Hamadani, Mehdi, Usmani, Saad, and Kumar, Shaji

Published
2022
Full Text
View/download PDF

25. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Author

San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, and Bahlis, Nizar J.

Published
2022
Full Text
View/download PDF

26. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Author

Dimopoulos, Meletios, San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan, Sutherland, Heather, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin, Prince, H, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar, Chari, Ajai, ORourke, Lisa, Wu, Kaida, Schecter, Jordan, Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A, Khokhar, Nushmia, Avet-Loiseau, Hervé, and Usmani, Saad

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neoplasm, Residual, Outcome Assessment, Health Care
Abstract

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P12 and ≤12 months and >6 and ≤6 months. No new safety signals were observed. In relapsed/refractory multiple myeloma patients, daratumumab plus lenalidomide/dexamethasone continued to improve progression-free survival and deepen responses versus lenalidomide/dexamethasone. Trial Registration: clinicaltrials.gov identifier: 02076009.

Published
2018

27. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Goodyear, Carl S, primary, Patel, Amit, additional, Barnes, Eleanor, additional, Willicombe, Michelle, additional, Siebert, Stefan, additional, de Silva, Thushan I, additional, Snowden, John A, additional, Lim, Sean H, additional, Bowden, Sarah J, additional, Billingham, Lucinda, additional, Richter, Alex, additional, Carroll, Miles, additional, Carr, Edward J, additional, Beale, Rupert, additional, Rea, Daniel, additional, Parry, Helen, additional, Pirrie, Sarah, additional, Lim, Zixiang, additional, Satsangi, Jack, additional, Dunachie, Susanna J, additional, Cook, Gordon, additional, Miller, Paul, additional, Basu, Neil, additional, Gilmour, Ashley, additional, Hodgkins, Anne-Marie, additional, Evans, Lili, additional, Hughes, Ana, additional, Longet, Stephanie, additional, Meacham, Georgina, additional, Yong, Kwee L, additional, A'Hearne, Matthew J, additional, Koh, Mickey B C, additional, Burns, Siobhan O, additional, Orchard, Kim, additional, Paterson, Caron, additional, McIlroy, Graham, additional, Murray, Sam M, additional, Thomson, Tina, additional, Dimitriadis, Stavros, additional, Goulston, Lyndsey, additional, Miller, Samantha, additional, Keillor, Victoria, additional, Prendecki, Maria, additional, Thomas, David, additional, Kirkham, Amanda, additional, McInnes, Iain B, additional, Kearns, Pamela, additional, Beesley, Richard, additional, Churchill, Vicky, additional, Insch, Elspeth, additional, Loughton, Holly, additional, MacDonald, Eilean, additional, Lax, Siân, additional, Lowe, Faye, additional, Magwaro, Sophia, additional, Gradwell, Mark, additional, Kinsella, Francesca, additional, Rolfe, Hayley, additional, McIntyre, Stacey, additional, Mortimer, Paige, additional, Al-Taei, Saly, additional, Tadros, Susan, additional, Workman, Sarita, additional, Arnott, Maxine, additional, Brock, James, additional, Melville, Andrew, additional, Najm, Aurelie, additional, Rutherford, Matthew, additional, Sunzini, Flavia, additional, Herman, Lou S, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Wu, Mary Y, additional, Selby, Rachael, additional, Clay, Jennifer, additional, Hutchison, Clare, additional, Lown, Robert, additional, Lwin, May N, additional, Meardon, Naomi, additional, Kelleher, Peter, additional, Lightstone, Liz, additional, Walters, Thomas, additional, Denyer, Jayne, additional, Ibrahim, Rahima, additional, Gleeson, Sarah, additional, Martin, Paul, additional, McAdoo, Stephen, additional, Baker, Helena, additional, Horswill, Sarah, additional, Parungao, Nina, additional, Saich, Stephen, additional, Cullinane, James, additional, Irwin, Sophie, additional, Klenerman, Paul, additional, Marjot, Thomas, additional, Chakraverty, Ronjon, additional, Holroyd, Christopher, additional, Kavi, Janki, additional, Trown, Doreen, additional, Babbage, Gavin, additional, Chackathayil, Julia, additional, Faria, Patricia, additional, Ingham, Karen, additional, Miah, Murad, additional, Miranda, Mauro, additional, O'Reilly, Nicola, additional, Smith, Callie, additional, Driver, Kimberley, additional, Gauntlett, Kaylee, additional, Farthing, Andrew, additional, Rundell, Suzann, additional, Smith, Emily, additional, Tong, Andrew, additional, Woolcock, Kieran, additional, Hanke, Daniel, additional, Laidlaw, Stephen, additional, Malik, Zainab, additional, Nguyen, Dung, additional, Provine, Nicholas, additional, Tipton, Tom, additional, and Walker, Victoria, additional

Published
2024
Full Text
View/download PDF

28. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Sonneveld, Pieter, Facon, Thierry, San-Miguel, Jesus, Avet-Loiseau, Hervé, Mohty, Mohamad, Mateos, Maria-Victoria, Moreau, Philippe, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Engelhardt, Monika, Driessen, Christoph, Cook, Gordon, Dimopoulos, Melitios A, Gay, Francesca, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Schreder, Martin, Abildgaard, Niels, Hajek, Roman, Zojer, Niklas, Kastritis, Efstathios, Broijl, Annemiek, Schjesvold, Fredrik, Boccadoro, Mario, and Terpos, Evangelos

Published
2021
Full Text
View/download PDF

32. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

Author

Croft, James, Ellis, Sidra, Sherborne, Amy L., Sharp, Kim, Price, Amy, Jenner, Matthew W., Drayson, Mark T., Owen, Roger G., Chown, Sally, Lindsay, Jindriska, Karunanithi, Kamaraj, Hunter, Hannah, Gregory, Walter M., Davies, Faith E., Morgan, Gareth J., Cook, Gordon, Atanesyan, Lilit, Savola, Suvi, Cairns, David A., Jackson, Graham, Houlston, Richard S., and Kaiser, Martin F.

Published
2021
Full Text
View/download PDF

33. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

36. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.

Author

Irving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew, and McQuilten, Zoe K.

Subjects
PLASMA cells, MULTIPLE myeloma, STEM cell transplantation, THERAPEUTICS, BONE marrow cells, SURVIVAL analysis (Biometry)
Abstract

Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients and clinicians with long-term prognostic information nor policymakers with the full body of evidence needed to perform economic evaluation of new therapies or make reimbursement decisions. To address these limitations of the available evidence, this study aimed to develop and validate the EpiMAP Myeloma model, a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. Risk equations were estimated using the Australian and New Zealand Myeloma & Related Diseases Registry after multiple imputation of missing data. Risk equation coefficients were combined with multiple myeloma patients at diagnosis from the Registry to perform the simulation. The model was validated with 100 bootstraps of an out-of-sample prediction analysis using a 70/30 split of the 4,121 registry patients diagnosed between 2009 and 2023, resulting in 2,884 and 1,237 patients in the training and validation cohorts, respectively. For 90% of the 120 months in the 10-year post-diagnosis period, there was no significant difference in overall survival between the validation and simulated cohorts. These results highlight that the EpiMAP Myeloma model is robust at predicting multiple myeloma disease outcomes and treatment pathways in Australia & New Zealand. In the future, clinicians will be able to use the EpiMAP Myeloma model to provide personalised estimates of life expectancy to patients based on their specific characteristics, disease stage, and response to treatment. Policymakers will also be able to use the model to perform economic evaluation, to forecast the number of patients receiving treatment at different stages, and to determine the downstream impact of listing new, effective therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making.

Author

Baldwin, David, Carmichael, Jonathan, Cook, Gordon, Navani, Neal, Peach, James, Slater, Ruth, Wheatstone, Pete, Wilkins, Julia, Allen-Delingpole, Nicola, Kerr, Cicely EP, and Siddiqui, Khalid

Subjects
OVERALL survival, DRUG accessibility, QUALITY of life, DRUG approval, MULTIPLE myeloma
Abstract

Duration of overall survival in patients with cancer has lengthened due to earlier detection and improved treatments. However, these improvements have created challenges in assessing the impact of newer treatments, particularly those used early in the treatment pathway. As overall survival remains most decision-makers' preferred primary endpoint, therapeutic innovations may take a long time to be introduced into clinical practice. Moreover, it is difficult to extrapolate findings to heterogeneous populations and address the concerns of patients wishing to evaluate everyday quality and extension of life. There is growing interest in the use of surrogate or interim endpoints to demonstrate robust treatment effects sooner than is possible with measurement of overall survival. It is hoped that they could speed up patients' access to new drugs, combinations, and sequences, and inform treatment decision-making. However, while surrogate endpoints have been used by regulators for drug approvals, this has occurred on a case-by-case basis. Evidence standards are yet to be clearly defined for acceptability in health technology appraisals or to shape clinical practice. This article considers the relevance of the use of surrogate endpoints in cancer in the UK context, and explores whether collection and analysis of real-world UK data and evidence might contribute to validation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

41. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Author

Vijenthira, Abi, Gong, Inna Y., Fox, Thomas A., Booth, Stephen, Cook, Gordon, Fattizzo, Bruno, Martín-Moro, Fernando, Razanamahery, Jerome, Riches, John C., Zwicker, Jeff, Patell, Rushad, Vekemans, Marie Christiane, Scarfò, Lydia, Chatzikonstantinou, Thomas, Yildiz, Halil, Lattenist, Raphaël, Mantzaris, Ioannis, Wood, William A., and Hicks, Lisa K.

Published
2020
Full Text
View/download PDF

43. Genomic Classification and Individualized Prognosis in Multiple Myeloma

Author

Maura, Francesco, primary, Rajanna, Arjun Raj, additional, Ziccheddu, Bachisio, additional, Poos, Alexandra M., additional, Derkach, Andriy, additional, Maclachlan, Kylee, additional, Durante, Michael, additional, Diamond, Benjamin, additional, Papadimitriou, Marios, additional, Davies, Faith, additional, Boyle, Eileen M., additional, Walker, Brian, additional, Hultcrantz, Malin, additional, Silva, Ariosto, additional, Hampton, Oliver, additional, Teer, Jamie K., additional, Siegel, Erin M., additional, Bolli, Niccolò, additional, Jackson, Graham H., additional, Kaiser, Martin, additional, Pawlyn, Charlotte, additional, Cook, Gordon, additional, Kazandjian, Dickran, additional, Stein, Caleb, additional, Chesi, Marta, additional, Bergsagel, Leif, additional, Mai, Elias K., additional, Goldschmidt, Hartmut, additional, Weisel, Katja C., additional, Fenk, Roland, additional, Raab, Marc S., additional, Van Rhee, Fritz, additional, Usmani, Saad, additional, Shain, Kenneth H., additional, Weinhold, Niels, additional, Morgan, Gareth, additional, and Landgren, Ola, additional

Published
2024
Full Text
View/download PDF

45. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

47. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Author

Terpos, Evangelos, Engelhardt, Monika, Cook, Gordon, Gay, Francesca, Mateos, Maria-Victoria, Ntanasis-Stathopoulos, Ioannis, van de Donk, Niels W. C. J., Avet-Loiseau, Hervé, Hajek, Roman, Vangsted, Annette Juul, Ludwig, Heinz, Zweegman, Sonja, Moreau, Philippe, Einsele, Hermann, Boccadoro, Mario, San Miguel, Jesus, Dimopoulos, Meletios A., and Sonneveld, Pieter

Published
2020
Full Text
View/download PDF

48. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Author

Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, and San-Miguel, Jesus

Published
2020
Full Text
View/download PDF

50. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Author

Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, and Morgan, Gareth J

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results